Enigmatic ImClone

Enigmatic ImClone
Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. But such is the case with ImClone Systems, as investors struggle for clues on the long-term direction of this enigma.

Click here for reuse options!
Copyright 2003 Biotechblog

Leave a Reply

%d bloggers like this: